← Leaderboards
Michael H Weisman
University Of California San Diego
$0
Attributed
$0
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 5
By mechanism
M01$0 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Robert S Zeiger$5,714,247
- Michael G. Ziegler$7,592,003
- Edward H. Koo$17,601,880
- Dilip V Jeste$42,629,237
- Salvatore Albani$3,830,252
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchDrug Screening /EvaluationHuman Therapy EvaluationSign /SymptomJoint DisorderCombination ChemotherapyRheumatoid ArthritisMethotrexateAntiantibodyDosagePharmacokineticsQuality Of LifeSkeletal Disorder ChemotherapyOsteoarthritisPathologic ProcessPlacebosRemission /RegressionTumor Necrosis Factor AlphaAcute Disease /DisorderAntirheumatic AgentsChimeric ProteinsChloroquineCorticosteroids
Grant awards (45)
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2001 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2001 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2000 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2000 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2000 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR